Equality impact assessment – Topic selection and scoping

The UroLift System for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the development of the briefing note or during the Committee meeting, and, if so, what are they?

   No equality issues were identified during the development of the briefing note. It was noted that lower urinary tract symptoms secondary to benign prostatic hyperplasia are more prevalent in black men than men of white or Asian origin. This is a function of the clinical condition, not of the technology.

   No equality issues were identified at the Committee meeting but it was noted that benign prostatic hyperplasia is associated with older patients, and that age is a protected characteristic under the 2010 Equality Act.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

   No action required.

3. Does the scope need to highlight any potential equality issues? If so, how?

   No equality issues were identified during the development of the briefing note or at the Committee meeting. Therefore, no additional attention is required regarding equality issues.
No action required.

Approved by Associate Director (name): Mark Campbell
Date: [27/11/14]